Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Wnt signaling inhibitor APL-5125

An orally bioavailable small molecule kinase inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, Wnt signaling inhibitor APL-5125 targets and binds to an as of yet undisclosed kinase in the Wnt signaling pathway, thereby preventing Wnt-mediated signaling. This may inhibit growth of tumor cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is upregulated in many cancers and plays a key role in tumor cell proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	kinase inhibitor APL-5125
Code name:	APL 5125 APL-5125 APL5125

Wnt signaling inhibitor APL-5125

Search NCI's Drug Dictionary